{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:05:05Z","timestamp":1793239505835,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.drudis.2023.103757","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T11:59:51Z","timestamp":1693396791000},"page":"103757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic targeting of the complement system in ocular disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Sonika","family":"Rathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafiq","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ueffing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-8355","authenticated-orcid":false,"given":"Simon J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103757_b0005","doi-asserted-by":"crossref","first-page":"9945725","DOI":"10.1155\/2021\/9945725","article-title":"Complement inhibitors in age-related macular degeneration: a potential therapeutic option","volume":"2021","author":"Qin","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.drudis.2023.103757_b0010","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2023.103757_b0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/pro.5560060201","article-title":"The internal thioester and the covalent binding properties of the complement proteins C3 and C4","volume":"6","author":"Law","year":"1997","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0020","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0025","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","article-title":"Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets","volume":"190","author":"Xie","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2023.103757_b0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1084\/jem.144.5.1147","article-title":"Modulation of the alternative complement pathways by beta 1 H globulin","volume":"144","author":"Whaley","year":"1976","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2023.103757_b0035","doi-asserted-by":"crossref","first-page":"12839","DOI":"10.1073\/pnas.1102167108","article-title":"Structural basis for complement factor I control and its disease-associated sequence polymorphisms","volume":"108","author":"Roversi","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.drudis.2023.103757_b0040","doi-asserted-by":"crossref","first-page":"13236","DOI":"10.1073\/pnas.1106746108","article-title":"Unique structure of iC3b resolved at a resolution of 24 A by 3D-electron microscopy","volume":"108","author":"Alcorlo","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.drudis.2023.103757_b0045","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.4049\/jimmunol.156.12.4821","article-title":"Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component","volume":"156","author":"Lambris","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0050","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.129.5.2051","article-title":"Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity","volume":"129","author":"Ross","year":"1982","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0055","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1084\/jem.156.6.1739","article-title":"Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes","volume":"156","author":"Medof","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2023.103757_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.596415","article-title":"Tuning the functionality by splicing: factor H and its alternative splice variant FHL-1 share a gene but not all functions","volume":"11","author":"Mannes","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fimmu.2015.00025","article-title":"Complementing the sugar code: role of GAGs and sialic acid in complement regulation","volume":"6","author":"Langford-Smith","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2013.00412","article-title":"The proteoglycan glycomatrix: a sugar microenvironment essential for complement regulation","volume":"4","author":"Clark","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0075","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.4049\/jimmunol.1201751","article-title":"Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions","volume":"190","author":"Clark","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jcm4010018","article-title":"Role of factor H and related proteins in regulating complement activation in the macula, and relevance to age-related macular degeneration","volume":"4","author":"Clark","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2023.103757_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660194","article-title":"A family affair: addressing the challenges of factor H and the related proteins","volume":"12","author":"Poppelaars","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0090","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41467-020-14499-3","article-title":"Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration","volume":"11","author":"Cipriani","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103757_b0095","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ajhg.2021.06.002","article-title":"Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration","volume":"108","author":"Lores-Motta","year":"2021","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.drudis.2023.103757_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","article-title":"Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy","volume":"45","author":"Whitmore","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0105","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.ajpath.2014.07.017","article-title":"The membrane attack complex in aging human choriocapillaris","volume":"184","author":"Mullins","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2023.103757_b0110","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1167\/iovs.15-17009","article-title":"Assessment of proteins associated with complement activation and inflammation in maculae of human donors homozygous risk at chromosome 1 CFH-to-F13B","volume":"56","author":"Keenan","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0115","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ajpath.2019.04.005","article-title":"Choriocapillaris degeneration in geographic atrophy","volume":"189","author":"Sohn","year":"2019","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2023.103757_b0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"10.1016\/j.drudis.2023.103757_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000099251","article-title":"The induction of anterior chamber-associated immune deviation","volume":"92","author":"Niederkorn","year":"2007","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.drudis.2023.103757_b0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm814","article-title":"Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells","volume":"9","author":"Sohn","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2023.103757_b0135","first-page":"3492","article-title":"Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins","volume":"41","author":"Sohn","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0140","first-page":"3579","article-title":"Differential expression of the complement regulatory proteins in the human eye","volume":"34","author":"Bora","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00281-017-0649-6","article-title":"The eye as a complement dysregulation hotspot","volume":"40","author":"Clark","year":"2018","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.drudis.2023.103757_b0150","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.drudis.2023.103757_b0155","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/archopht.1980.01020030342023","article-title":"Alternate and classical pathway components of complement in the normal cornea","volume":"98","author":"Mondino","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2023.103757_b0160","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1076\/ceyr.21.5.856.5539","article-title":"Release of complement regulatory proteins from ocular surface cells in infections","volume":"21","author":"Cocuzzi","year":"2000","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.48378","article-title":"Complement and CD4+ T cells drive context-specific corneal sensory neuropathy","volume":"8","author":"Royer","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2023.103757_b0170","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1038\/s41598-021-89818-9","article-title":"An intact complement system dampens cornea inflammation during acute primary HSV-1 infection","volume":"11","author":"Filiberti","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103757_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102351","article-title":"Uveitis: autoimmunity\u2026 and beyond","volume":"18","author":"Bertrand","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.drudis.2023.103757_b0180","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1167\/iovs.12-9478","article-title":"Association of C2 and CFB polymorphisms with anterior uveitis","volume":"53","author":"Yang","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0185","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/eye.2016.146","article-title":"Association of CD59 and CFH polymorphisms with acute anterior uveitis in Chinese population","volume":"30","author":"Wang","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2023.103757_b0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0198-8859(88)90032-8","article-title":"Association of complement allotype C4B2 with anterior uveitis","volume":"21","author":"Wakefield","year":"1988","journal-title":"Hum Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0195","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.ajo.2013.01.019","article-title":"Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis","volume":"155","author":"Thompson","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2023.103757_b0200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.reuma.2020.07.007","article-title":"Serum immunoglobulin levels, complement components 3 and 4, HLA-B27 allele and spondyloarthropathy in patients with non-infectious anterior uveites","volume":"17","author":"Torres Rives","year":"2021","journal-title":"Reumatol Clin (Engl Ed)."},{"key":"10.1016\/j.drudis.2023.103757_b0205","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1167\/iovs.05-1062","article-title":"The complement system plays a critical role in the development of experimental autoimmune anterior uveitis","volume":"47","author":"Jha","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.molimm.2010.08.006","article-title":"Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU)","volume":"48","author":"Manickam","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0215","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.exer.2005.07.011","article-title":"Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis","volume":"82","author":"Read","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0220","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1189\/jlb.3A0415-157R","article-title":"Complement anaphylatoxin receptors C3aR and C5aR are required in the pathogenesis of experimental autoimmune uveitis","volume":"99","author":"Zhang","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.drudis.2023.103757_b0225","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3389\/fimmu.2017.01116","article-title":"Complement component C4 regulates the development of experimental autoimmune uveitis through a T cell-intrinsic mechanism","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0230","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1167\/iovs.08-3264","article-title":"Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis","volume":"50","author":"An","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0235","doi-asserted-by":"crossref","first-page":"e0162229","DOI":"10.1371\/journal.pone.0162229","article-title":"Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990\u20132010: a meta-analysis","volume":"11","author":"Bourne","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2023.103757_b0240","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ajo.2013.05.027","article-title":"Lifetime risk of blindness in open-angle glaucoma","volume":"156","author":"Peters","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2023.103757_b0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","article-title":"Definition of glaucoma: clinical and experimental concepts","volume":"40","author":"Casson","year":"2012","journal-title":"Clin Exp Ophthalmol."},{"key":"10.1016\/j.drudis.2023.103757_b0250","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017269","article-title":"The complex role of neuroinflammation in glaucoma","volume":"4","author":"Soto","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2023.103757_b0255","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exer.2017.02.014","article-title":"Lasker\/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Neuroinflammation in glaucoma: a new opportunity","volume":"157","author":"Williams","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0260","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-2094-10-76","article-title":"Deficiency of complement component 5 ameliorates glaucoma in DBA\/2J mice","volume":"10","author":"Howell","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.drudis.2023.103757_b0265","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ymthe.2018.08.017","article-title":"Complement C3-targeted gene therapy restricts onset and progression of neurodegeneration in chronic mouse glaucoma","volume":"26","author":"Bosco","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2023.103757_b0270","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1167\/iovs.05-0830","article-title":"Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes","volume":"47","author":"Stasi","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0275","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI44646","article-title":"Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma","volume":"121","author":"Howell","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2023.103757_b0280","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1167\/iovs.10-5289","article-title":"Oxidative stress and the regulation of complement activation in human glaucoma","volume":"51","author":"Tezel","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0285","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.exer.2006.03.002","article-title":"Retinal synthesis and deposition of complement components induced by ocular hypertension","volume":"83","author":"Kuehn","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0290","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103757_b0295","doi-asserted-by":"crossref","first-page":"1313027","DOI":"10.1155\/2016\/1313027","article-title":"Genetic investigation of complement pathway genes in type 2 diabetic retinopathy: an inflammatory perspective","volume":"2016","author":"Yang","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.drudis.2023.103757_b0300","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021. Available at www.diabetesatlas.org"},{"key":"10.1016\/j.drudis.2023.103757_b0305","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0310","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/cells12091342","article-title":"Retinal cell damage in diabetic retinopathy","volume":"12","author":"Zhou","year":"2023","journal-title":"Cells."},{"key":"10.1016\/j.drudis.2023.103757_b0315","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1021\/pr800112g","article-title":"Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy","volume":"7","author":"Gao","year":"2008","journal-title":"J Proteome Res"},{"key":"10.1016\/j.drudis.2023.103757_b0320","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.2337\/diabetes.51.12.3499","article-title":"Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy","volume":"51","author":"Zhang","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2023.103757_b0325","doi-asserted-by":"crossref","first-page":"e0149704","DOI":"10.1371\/journal.pone.0149704","article-title":"Association of complement C5 gene polymorphisms with proliferative diabetic retinopathy of type 2 diabetes in a Chinese Han population","volume":"11","author":"Xu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2023.103757_b0330","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/brain\/awz188","article-title":"Early complement genes are associated with visual system degeneration in multiple sclerosis","volume":"142","author":"Fitzgerald","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2023.103757_b0335","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fncel.2014.00380","article-title":"Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis","volume":"8","author":"Orsini","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.drudis.2023.103757_b0340","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.imbio.2015.11.007","article-title":"Age-related macular degeneration: complement in action","volume":"221","author":"van Lookeren","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.drudis.2023.103757_b0345","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.drudis.2023.103757_b0350","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.drudis.2023.103757_b0355","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/imr.13145","article-title":"Age-related macular degeneration: a disease of extracellular complement amplification","volume":"313","author":"de Jong","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2023.103757_b0360","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0365","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molimm.2014.06.032","article-title":"Genetic variants in the complement system predisposing to age-related macular degeneration: a review","volume":"61","author":"Schramm","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2023.103757_b0375","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajhg.2021.05.015","article-title":"Beyond factor H: the impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations","volume":"108","author":"Cipriani","year":"2021","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.drudis.2023.103757_b0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0385","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1006\/exer.2001.1094","article-title":"Complement activation and inflammatory processes in Drusen formation and age related macular degeneration","volume":"73","author":"Johnson","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0390","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.62.7.26","article-title":"Differential and altered spatial distribution of complement expression in age-related macular degeneration","volume":"62","author":"Demirs","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/path.5867","article-title":"Local factor H production by human choroidal endothelial cells mitigates complement deposition: implications for macular degeneration","volume":"257","author":"Mulfaul","year":"2022","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2023.103757_b0400","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3389\/fphar.2019.01381","article-title":"Intravitreal therapy against the complement factor C5 prevents retinal degeneration in an experimental autoimmune glaucoma model","volume":"10","author":"Reinehr","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2023.103757_b0405","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00441-020-03240-7","article-title":"Preservation of optic nerve structure by complement inhibition in experimental glaucoma","volume":"382","author":"Gassel","year":"2020","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.drudis.2023.103757_b0410","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2014-1099","article-title":"Role of complement and complement regulatory proteins in the complications of diabetes","volume":"36","author":"Ghosh","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/j.drudis.2023.103757_b0415","doi-asserted-by":"crossref","first-page":"e79661","DOI":"10.1371\/journal.pone.0079661","article-title":"Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice","volume":"8","author":"Adhi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2023.103757_b0420","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103757_b0425","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0430","unstructured":"Apellis Pharmaceuticals. FDA Approves SYFOVRE\u2122 (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness. February 17, 2023."},{"key":"10.1016\/j.drudis.2023.103757_b0435","unstructured":"Apellis Pharmaceuticals. Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy. December 16, 2022."},{"key":"10.1016\/j.drudis.2023.103757_b0440","series-title":"Immunobiology: The Immune System in Health and Disease","article-title":"The complement system and innate immunity","author":"Janeway","year":"2001"},{"key":"10.1016\/j.drudis.2023.103757_b0445","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.imbio.2019.05.003","article-title":"The story of complement factor I","volume":"224","author":"Lachmann","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.drudis.2023.103757_b0450","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jim.2018.03.013","article-title":"A novel and sensitive functional assay for complement factor I based on the third proteolytic clip of C3b","volume":"457","author":"Lachmann","year":"2018","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.drudis.2023.103757_b0455","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/pharmaceutics15051484","article-title":"Delivery systems in ocular retinopathies: the promising future of intravitreal hydrogels as sustained-release scaffolds","volume":"15","author":"Rafael","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2023.103757_b0460","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1167\/iovs.11-7909","article-title":"Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera","volume":"52","author":"Clark","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0465","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3389\/fimmu.2017.01778","article-title":"Bruch\u2019s membrane compartmentalizes complement regulation in the eye with implications for therapeutic design in age-related macular degeneration","volume":"8","author":"Clark","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109134","article-title":"New approaches to the treatment of age-related macular degeneration (AMD)","volume":"221","author":"Csaky","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0475","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3390\/jcm12082870","article-title":"Bruch\u2019s membrane: a key consideration with complement-based therapies for age-related macular degeneration","volume":"12","author":"Hammadi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2023.103757_b0480","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/eye.1990.43","article-title":"Control of retinal and choroidal blood flow","volume":"4","author":"Bill","year":"1990","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2023.103757_b0485","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0490","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaophthalmol.2021.6067","article-title":"Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the FILLY Randomized Clinical Trial","volume":"140","author":"Nittala","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.drudis.2023.103757_b0495","first-page":"1500","article-title":"Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies","volume":"63","author":"Goldberg","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0500","unstructured":"Apellis Pharmaceuticals. Syfovre Prescribing Information. Available at https:\/\/pi.apellis.com\/files\/PI_SYFOVRE.pdf."},{"key":"10.1016\/j.drudis.2023.103757_b0505","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2021.08.018","article-title":"Inhibition of complement factor 3 in geographic atrophy with NGM621: phase 1 dose-escalation study results","volume":"235","author":"Wykoff","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2023.103757_b0510","unstructured":"NGM Bio. NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. October 17, 2022. Available at https:\/\/ir.ngmbio.com\/node\/9586\/pdf."},{"key":"10.1016\/j.drudis.2023.103757_b0515","unstructured":"NGM Bio. Corporate Overview. February, 2023. Available at https:\/\/ir.ngmbio.com\/static-files\/74d87528-d8b7-4b1f-aff7-033e285a1742."},{"key":"10.1016\/j.drudis.2023.103757_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108391","article-title":"Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates","volume":"214","author":"Hughes","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0525","unstructured":"Apellis Pharmaceuticals. Company Presentation. June 30, 2021. Available at https:\/\/investors.apellis.com\/static-files\/c1acbf17-a612-4522-b1bd-1b333b68bed1."},{"key":"10.1016\/j.drudis.2023.103757_b0530","unstructured":"Apellis Pharmaceuticals. Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results. February 28, 2022. Available at https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-3."},{"key":"10.1016\/j.drudis.2023.103757_b0535","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2177","article-title":"Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2023.103757_b0540","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2022.11.016","article-title":"A novel bispecific fusion protein targeting C3b\/C4b and VEGF in patients with nAMD: a randomized, open-label, phase 1b study","volume":"248","author":"Jia","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2023.103757_b0545","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0550","unstructured":"Iveric Bio. Iveric Bio Announces Positive Topline Data from Zimura\u00ae GATHER2 Phase 3 Clinical Trial in Geographic Atrophy. September 6, 2022. Available at https:\/\/investors.ivericbio.com\/news-releases\/news-release-details\/iveric-bio-announces-positive-topline-data-zimurar-gather2-phase."},{"key":"10.1016\/j.drudis.2023.103757_b0555","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0560","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/iovs.64.2.3","article-title":"Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates","volume":"64","author":"Grover","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0565","unstructured":"Annexon Biosciences. Annexon topline data from ARCHER Phase 2 trial of ANX007 in geographic atrophy demonstrated statistically significant, dose-dependent preservation of visual function. May 24, 2023. Available at https:\/\/ir.annexonbio.com\/news-releases\/news-release-details\/annexon-topline-data-archer-phase-2-trial-anx007-geographic."},{"key":"10.1016\/j.drudis.2023.103757_b0570","first-page":"4305","article-title":"Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD","volume":"61","author":"Jaffe","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0575","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.drudis.2023.103757_b0580","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2023.103757_b0585","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.drudis.2023.103757_b0590","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/tvst.11.10.37","article-title":"Danicopan, an oral complement factor D inhibitor, exhibits high and sustained exposure in ocular tissues in preclinical studies","volume":"11","author":"Boyer","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.drudis.2023.103757_b0595","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.4049\/jimmunol.1401613","article-title":"Identification of factor H-like protein 1 as the predominant complement regulator in Bruch\u2019s membrane: implications for age-related macular degeneration","volume":"193","author":"Clark","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0600","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1038\/s41598-021-93708-5","article-title":"FHL-1 interacts with human RPE cells through the alpha5beta1 integrin and confers protection against oxidative stress","volume":"11","author":"Choudhury","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103757_b0605","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.3390\/ijms22168727","article-title":"CFH loss in human RPE cells leads to inflammation and complement system dysregulation via the NF-\u03baB pathway","volume":"22","author":"Armento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0610","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/antiox10121944","article-title":"mTOR inhibition via rapamycin treatment partially reverts the deficit in energy metabolism caused by FH loss in RPE cells","volume":"10","author":"Merle","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.drudis.2023.103757_b0615","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1038\/s41467-021-27488-x","article-title":"Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103757_b0620","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/02713683.2022.2053725","article-title":"A novel full-length recombinant human complement factor H (CFH; GEM103) for the treatment of age-related macular degeneration shows similar in vitro functional activity to native CFH","volume":"47","author":"Biggs","year":"2022","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100154","article-title":"A phase I, single ascending dose study of GEM103 (recombinant human complement factor H) in patients with geographic atrophy","volume":"2","author":"Khanani","year":"2022","journal-title":"Ophthalmol Sci."},{"key":"10.1016\/j.drudis.2023.103757_b0630","unstructured":"Evaluate Vantage. No land grab for Gemini in geographic atrophy. June 23, 2021. Available at https:\/\/www.evaluate.com\/vantage\/articles\/news\/trial-results\/no-land-grab-gemini-geographic-atrophy"},{"key":"10.1016\/j.drudis.2023.103757_b0635","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2023.103757_b0640","unstructured":"Eichenbaum D. Surgical delivery strategies and gene therapy for atrophic AMD. Paper presented at Retina Society 2022. November 2, 2022; Pasadena, CA. Available at https:\/\/www.gyroscopetx.com\/wp-content\/uploads\/2022\/11\/Retina-Society-2022-Gene-Delivery-Strategies_FOCUS-Study_David-Eichenbaum_FINAL.pdf"},{"key":"10.1016\/j.drudis.2023.103757_b0645","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/iovs.61.6.18","article-title":"Rare genetic variants in complement factor I lead to low FI plasma levels resulting in increased risk of age-related macular degeneration","volume":"61","author":"Hallam","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0650","first-page":"3861","article-title":"Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels","volume":"24","author":"Kavanagh","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2023.103757_b0655","unstructured":"Johnson & Johnson. Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting. October 1, 2022. Available at https:\/\/www.jnj.com\/janssen-announces-late-breaking-data-from-two-gene-therapy-programs-at-the-american-academy-of-ophthalmology-2022-annual-meeting"},{"key":"10.1016\/j.drudis.2023.103757_b0660","unstructured":"Cohen MN. Phase 1 study of JNJ-81201887 gene therapy in geographic atrophy (GA) due to age-related macular degeneration (AMD). Abstract #30071749. Paper presented at the 2022 American Academy of Ophthalmology Annual Meeting."},{"key":"10.1016\/j.drudis.2023.103757_b0665","first-page":"2672","article-title":"A first in human study of intravitreal (IVT) CLG561 in subjects with advanced age-related macular degeneration (AMD)","volume":"57","author":"Glazer","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2023.103757_b0670","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2018.08.006","article-title":"Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK consortium","volume":"126","author":"Merle","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0675","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ophtha.2020.11.024","article-title":"Genetic risk, lifestyle, and age-related macular degeneration in Europe: the EYE-RISK consortium","volume":"128","author":"Colijn","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0680","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/978-1-4614-4711-5_3","article-title":"The blood-retina barrier: tight junctions and barrier modulation","volume":"763","author":"Campbell","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2023.103757_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100846","article-title":"The cell biology of the retinal pigment epithelium","author":"Lakkaraju","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.drudis.2023.103757_b0690","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/DDDT.S206355","article-title":"Complement system and age-related macular degeneration: drugs and challenges","volume":"13","author":"Wu","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2023.103757_b0695","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2017.00174","article-title":"Retinal gene therapy: surgical vector delivery in the translation to clinical trials","volume":"11","author":"Ochakovski","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1016\/j.drudis.2023.103757_b0700","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2023.103757_b0705","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ophtha.2020.08.031","article-title":"Predicting progression to advanced age-related macular degeneration from clinical, genetic, and lifestyle factors using machine learning","volume":"128","author":"Ajana","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2023.103757_b0710","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3390\/biom11111621","article-title":"Complement factor H loss in RPE cells causes retinal degeneration in a human RPE-porcine retinal explant co-culture model","volume":"11","author":"Armento","year":"2021","journal-title":"Biomolecules"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623002738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623002738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:06:25Z","timestamp":1761224785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623002738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1359644623002738"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103757","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of the complement system in ocular disease","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103757"}}